GENSIGHT BIOLOGICS S.A. Corporate Presentation
September 2020
A LEADING Gene Therapy BIOTECHNOLOGY COMPANY
GENSIGHT-BIOLOGICS.COM
Disclaimer
This document contains forward-looking statements and estimates made by the GenSight Biologics S.A. (the "Company"), including with respect to the anticipated future performance of the Company, its subsidiaries and affiliates, and the market in which they operate. They include all matters that are not historical facts. These forward-looking statements can be identified by the use of forward-looking terminology including the terms "developments," "estimates," "expects," "intends," "may," "milestones," "potential," "value," "time to market," "targeting," "on track," "planned," "will," "move to," or other variations or comparable terminology, or by discussions of strategy and funding, as well as the Company's, its subsidiaries' and affiliates' technology, and are based on financial and non-financial information, including projections as to the future regulatory situation and other information and assumptions. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may
depend upon factors that are beyond the Company's control. Therefore, actual results, the financial condition, performance or achievements of the Company, its subsidiaries and affiliates or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Forward-looking statements, forecasts and estimates only speak as of the date of this forward-looking statement, and no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. The Company, its subsidiaries and affiliates disclaim any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in the Company's expectations with regard thereto, or any events, or changes in conditions or circumstances on which any such statement, forecast or estimate is based.
2 September 2020 - non confidential
Corporate Overview - Transitioning from R&D to Commercial organization
GenSight at the forefront of Gene Therapy in ophthalmology
- Publicly traded Biotech company
- Seasoned management team with strong BioPharma and Financial markets experience
- Differentiated gene therapy approach forming a technology platform leveraging disruptive gene therapies in ophthalmology and broader
- Lead product (LUMEVOQ) targets mitochondrial disease
- Second compound (GS030) uses optogenetic technology
LUMEVOQ® (GS010) - Filed MAA in Europe in September 2020 and preparing for commercial launch in 2021
- Targeting the LHON ND4 market with high unmet medical need and no widely approved treatment
- Unparalleled clinical benefit demonstrated with LUVEMOQ® in Leber Hereditary Optic Neuropathy (LHON) in two Phase III studies
- +28/+26 ETDRS letters (i.e. over 5 lines on visual scale) improvement vs nadir(1) in the two- Phase III studies
- Clinically meaningful improvement on all Quality of Life parameters at week 96
- Visual improvement maintained at least 3 years post-treatment
Commercial strategy and manufacturing capabilities close to completion
- Bilateral injection priced at €700,000 / patient in French named patient
Temporary Authorization for Use
3 September 2020 - non confidential
Established in 2012 / IPO in 2016 | |
EuroNext Paris: | SIGHT |
Market Cap (July 3, 2020): | € 101m |
Avg 30-day Daily volume: | 0.8% of O/S |
Cash (June 30, 2020): | € 16.8m |
Improvement vs nadir in
REVERSE and RESCUE
+5
Lines
Seasoned Executive Team
Bernard Gilly | Thomas Gidoin | Magali Taiel |
Chief Executive Officer | Chief Financial Officer | Chief Medical Officer |
PIXIUM VISION (Since 2011) | DBV TECHNOLOGIES (2012-2015) | ProQR THERAPEUTICS (2016- |
Chairman of the Board, Founder | VP of Finance | 2018) |
FOVEA PHARMA (2005-2009) | IPSEN (2008-2011) | VP of Clinical Development |
ELI LILLY (2004-2016) | ||
Chairman & CEO - sold to Sanofi | UK Operations Controller (London) | |
SOFINNOVA PARTNERS (2000-2005) | Senior Financial Analyst (Paris) | Medical Department Lead |
ERNST & YOUNG (2007-2008) | PFIZER (2001-2004) | |
Managing Partner | ||
TRANSGENE (1992-2000) | Auditor | Medical Advisor |
SERVIER (1999-2001) | ||
Chairman & CEO | ||
Ph.D. in biology and bio-economics | R&D International Project Manager | |
MD, Board-certified ophthalmologist | ||
Catherine Cancian
Vice President Pharmaceutical
Operations
GENETHON (2015-2017)
Project Leader
SANOFI PASTEUR (1998-2014)
Industrial Operations and
Regulatory Affairs
Julio Benedicto
Vice President Marketing
IMS CONSULTING (2011-2017)
Principal
BOOZ & COMPANY (2010-2011)
Principal
MONITOR GROUP (1994-2009)
Global Account Manager
4 September 2020 - non confidential
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
Gensight Biologics SA published this content on 21 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 September 2020 10:59:04 UTC
